Directors and Senior Leadership

Mr Frank Condella was appointed to the Board on 30 May 2018 and was appointed Chair in September 2021.

Mr Condella, a US resident, has over 30 years of experience in senior executive roles in the global pharmaceutical industry. His operating experience includes CEO of Juniper Pharmaceuticals, a CDMO and specialty pharmaceutical company, which was subsequently sold to Catalent. Previously he served as CEO of Skyepharma Plc, President of European operations at IVAX (Teva), CEO of Faulding Pharmaceuticals, Vice President of Specialty Care Products at Roche and Vice President and General Manager of the Lederle Standard Products (Pfizer). Mr Condella’s previous board experience includes Chair of Skyepharma Plc until it merged with Vectura, Vice Chair of Vectura Plc, Independent Director for Fertin Pharma A/S (Denmark), Independent Director for Palladio Biosciences Inc (US), Independent Director of Prosonix ltd, Independent Director of Fulcrum Pharma plc, and Chair of the PKD Foundation. Mr Condella holds a Bachelor of Science in Pharmacy and an M.B.A. from Northeastern University, Boston.

Mr Condella is also Chair of the Remuneration and People Committee and the Nomination Committee and a member of the Science and Technology Committee

Shawn Patrick O’Brien has more than 35 years of global pharmaceutical industry experience building successful enterprises. He is the founding partner of Key BioPharma Partners providing advice to life science companies and capital providers. Previously, he was the Chairman and CEO of Genomind, a personalised mental health platform company and President and CEO of Cipher Pharmaceuticals, Inc., a specialty pharmaceutical company with a portfolio of commercial stage dermatology products. He was also President and CEO of three private biotechs including AltheRx Pharmaceuticals, Profectus BioSciences Inc. and Solstice Neurosciences. Mr O’Brien spent 17 years with AstraZeneca where he held multiple senior leadership positions in Canada and the US including Vice President of Commercial Operations for Emerging Brands, Vice President and Therapy Area Leader, Respiratory and Inflammation and Commercial and Development Group Director for the Oncology Therapeutic area. Mr O’Brien began his career at the Upjohn Company of Canada (part of Pfizer).

Mr O’Brien is the Non-executive Chairman of SFA Therapeutics and Alto Pharma. He is a board member and Co-Chair of the Hubert J.P. Schoemaker Classic (golf charity fundraiser) and an advisory board member of Greater Philadelphia Life Sciences Congress. He was a 9-year Board member of the Crozer Keystone Hospital System, a former board member of Cyrano, LLC and Melanovus LLC.

Mr O’Brien holds a Bachelor of Science in Microbiology and Immunology from the University of Western Ontario.

Mr Patrick Blake was appointed to the Board on 28 June 2018.

Mr Blake, a US resident, has over 30 years of global healthcare industry experience including more than 20 years at McKesson Corporation, one of the largest healthcare services and information technology companies globally, and more than 10 years at Baxter Healthcare Corporation. Most recently, he was Executive Vice President of McKesson Corporation and Group President of McKesson Technology Solutions which services the health IT needs of hospitals and health systems, payers, physicians, homecare agencies, retail pharmacies and manufacturers, a position he held from 2009 until 2017. Previously, he was President of McKesson Specialty Health, a business focussed on the US specialty/biotech sector and President of Customer Operations for McKesson Pharmaceutical (US). He is currently an Independent Director of Sutter Health and Deerfield Agency. Mr Blake holds a Bachelor of Arts in Economics from Denison University and an M.B.A. from Pepperdine Graziadio School of Business and Management.

Mr Blake is a member of the Audit & Risk Committee and the Remuneration and People Committee.

Ms Ann Custin was appointed to the Board on 23 March 2022.

Ms Ann Custin, a US resident, has almost 40 years of experience in the healthcare sector. Most recently, Ms Custin served as both CFO and Board Director of Siemens Medical Solutions (now Siemens Healthineers), a leading medical technology company with EUR20b in revenues. Prior to this role, she was Chief Operating and Financial Officer of Scient’x Group and President and CEO of USA Draeger Medical Systems. Ms Custin is a director of two women’s health focused companies – ASX-listed Volpara Health and NASDAQ-listed Establishment Labs. She has a Bachelor of Accounting from Queens College and a Certified Public Accountant.

Ms Custin is Chair of the Audit and Risk Committee.

Dr Kathryn MacFarlane was appointed to the Board on 1 February 2022.

Dr MacFarlane, a US resident, has more than 30 years of experience in the pharmaceutical industry. She is currently Founder and Managing Partner of SmartPharma LLC, offering commercial and strategic consulting services to pharmaceutical companies. Previously, she was Chief Commercial Officer at Agile Therapeutics, Vice President Women’s Health Care Marketing, Sales and New Product Planning at Warner Chilcott and Senior Director of Marketing at Parke-Davis (now Pfizer). Dr MacFarlane is a Director of RespireRx Pharmaceuticals, Inc., a member of the Purdue University School of Pharmacy Dean’s Advisory Council and a Founding Member and Advisor to IPhO. She also serves on the Board of Directors for INMED Partnerships for Children, an NGO. She has a Bachelor of Science and Doctor of Pharmacy from Purdue University and completed a Postdoctoral Fellowship with Rutgers University and Hoffmann- LaRoche.

Dr MacFarlane is a member of Mayne Pharma’s Science, Technology and Medical Committee; and the Nomination Committee.

Professor Bruce Robinson was appointed to the Board on 26 August 2014.

Professor Robinson, a practising Endocrinologist at Sydney’s Royal North Shore Hospital, is Former Dean of University of Sydney’s Sydney Medical School. Professor Robinson has been the head of the Cancer Genetics Unit at the Kolling Institute of Medical Research, Royal North Shore Hospital since 1989. Since 2001, Professor Robinson has been Chair of Hoc Mai Foundation, a major program in medical and health education and exchange with Vietnam. He is a Non-Executive Director of Cochlear Limited, Lorica and QBiotics Group Limited. He is a Board Member of the Woolcock Institute, is Chair of National Health and Medical Research Council and Chair of the Medical Benefits Review Taskforce.

Prof Robinson is Chair of Mayne Pharma’s Science, Technology and Medical Committee and a member of the Nominations Committee.

Mr David Petrie was appointed to the Board on 1 September 2022.

Mr David Petrie is an accomplished M&A executive with over 30 years of advisory experience in public and private mergers and acquisitions, capital management and debt and equity raisings. He is currently Principal at Stratford Advisory Group, an independent corporate and financial advisory firm. Previously, he spent 23 years at Merrill Lynch/Bank of America including Managing Director and Head of Investment Banking Melbourne. He has worked on more than 100 transactions across a range of market sectors including healthcare. Mr Petrie has a Bachelor of Commerce (Honours) and Bachelor of Law (Honours) from the University of Melbourne. He has been a CPA for 30 years and is admitted as Barrister and Solicitor of the Supreme Court of Victoria.

Mr Petrie is a member of Mayne Pharma’s Audit and Risk Committee; and the Remuneration and People Committee.

Shawn Patrick O’Brien has more than 35 years of global pharmaceutical industry experience building successful enterprises. He is the founding partner of Key BioPharma Partners providing advice to life science companies and capital providers. Previously, he was the Chairman and CEO of Genomind, a personalised mental health platform company and President and CEO of Cipher Pharmaceuticals, Inc., a specialty pharmaceutical company with a portfolio of commercial stage dermatology products. He was also President and CEO of three private biotechs including AltheRx Pharmaceuticals, Profectus BioSciences Inc. and Solstice Neurosciences. Mr O’Brien spent 17 years with AstraZeneca where he held multiple senior leadership positions in Canada and the US including Vice President of Commercial Operations for Emerging Brands, Vice President and Therapy Area Leader, Respiratory and Inflammation and Commercial and Development Group Director for the Oncology Therapeutic area. Mr O’Brien began his career at the Upjohn Company of Canada (part of Pfizer).

Mr O’Brien is the Non-executive Chairman of SFA Therapeutics and Alto Pharma. He is a board member and Co-Chair of the Hubert J.P. Schoemaker Classic (golf charity fundraiser) and an advisory board member of Greater Philadelphia Life Sciences Congress. He was a 9-year Board member of the Crozer Keystone Hospital System, a former board member of Cyrano, LLC and Melanovus LLC.

Mr O’Brien holds a Bachelor of Science in Microbiology and Immunology from the University of Western Ontario.

Frank Casty, MD has 30 years of global drug development experience including clinical development, medical and regulatory affairs and pharmacovigilance.  In addition to leading numerous NDA/MAA filings across multiple therapeutic areas, he has significant launch and lifecycle management experience and has held several enterprise-wide leadership positions.

Dr Casty has recently been a consultant to several large pharma and startup companies and serves as a Scientific Advisory Board member.  Previously, he was Head of Drug and Device Development at Mallinckrodt, SVP Global Medical Affairs and Drug Safety at Mylan and Head of Cardiovascular Development at Novartis.  Dr Casty spent more than 11 years at AstraZeneca where he held several senior leadership positions including VP US Strategic Development and Head of Global Clinical Development where he was responsible for all clinical, medical, pharmacology, and health economic activities across Oncology, Respiratory/Inflammation, Cardiovascular and CNS therapeutic areas.

Dr Casty received an MD from Temple University School of Medicine.  He completed a residency in Internal Medicine at Rush University and a fellowship in Pulmonary/Critical Care Medicine at the University of Vermont.

Brant joined Mayne Pharma in October 2018 and has more than 25 years of experience in the pharmaceutical industry including more than 15 years at Galderma Laboratories, a leading global dermatology and skin health company. Previously, he was Vice President and General Manager Dermatology at Sandoz US where he was responsible for brand and generic product portfolio with revenues of approximately US$500m. Prior to Sandoz, he was Vice President of New Business for Nestle Skin Health (parent entity of Galderma) and he was also Vice President of Sales and Marketing for Galderma US, where he led a 300+ person sales and marketing team and was responsible for more than US$1.0b of sales across prescription, over-the-counter and aesthetic dermatology markets.

Keith joined Mayne Pharma in 2015 and has more than 20 years of experience in the pharmaceutical industry. Keith has been instrumental in driving Mayne Pharma’s pipeline and the development of branded and generic products. He also worked at Metrics, Inc. for 14 years prior to its acquisition by Mayne Pharma. Keith has served as Vice President of Analytical Services for Mayne Pharma’s CDMO where he led all laboratory functions including laboratory operations, quality control unit, microbiology, analytical development and method validation, stability, and metrology comprising some 180 employees. Prior to this role, he worked at Salix Pharmaceuticals in technical operations supporting R&D, regulatory, and commercial activities. Keith holds degrees in both Chemistry and Business Administration.